FREDUN PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of FREDUN PHARMACEUTICALS have increased by 40.03% YoY .
The Earnings Per Share (EPS) of FREDUN PHARMACEUTICALS has increased by 42.61 % YoY. |
||
FREDUN PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 539730]
| Consolidated | Mar2026 | Mar2025 |
|---|---|---|
| Revenues | ₹635 Cr | ₹454 Cr |
| Expenses | ₹545 Cr | ₹401 Cr |
| Operating Profit (Excl OI) | ₹91 Cr | ₹52 Cr |
| Other Income | ₹3.66 Cr | ₹2.45 Cr |
| Interest | ₹39 Cr | ₹22 Cr |
| Depreciation | ₹8.25 Cr | ₹5.04 Cr |
| Profit Before Tax | ₹47 Cr | ₹27 Cr |
| Profit After Tax | ₹33 Cr | ₹20 Cr |
| Consolidated Net Profit | ₹33 Cr | ₹20 Cr |
| Earnings Per Share (Rs) | ₹59.61 | ₹41.80 |
| PAT Margin (%) | 5.13 | 4.35 |
| ROE(%) | 16.09 | 13.96 |
| ROCE(%) | 21.34 | 16.16 |
| Total Debt/Equity(x) | 0.84 | 1.18 |
Key Financials |
||
| Market Cap | : | ₹ 1,435.6 Cr |
| Revenue (TTM) | : | ₹ 639.1 Cr |
| Net Profit(TTM) | : | ₹ 37.5 Cr |
| EPS (TTM) | : | ₹ 68.1 |
| P/E (TTM) | : | 38.3 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| FREDUN PHARMACEUTICALS | 16% | 13.4% | 242.1% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.4% | -4.5% | 6.5% |
| DIVIS LABORATORIES | 0.1% | -2.5% | -0.1% |
| TORRENT PHARMACEUTICALS | -2.7% | 1.2% | 39.3% |
| CIPLA | -2.3% | -5.3% | -9.8% |
| DR REDDYS LABORATORIES | -0.5% | -4.7% | -5.4% |
| MANKIND PHARMA | -0.3% | -5.3% | -0.9% |
| LUPIN | -0.3% | 0.6% | 12.3% |
| ZYDUS LIFESCIENCES | -4% | 7.1% | 10.2% |
FREDUN PHARMACEUTICALS Revenues
[BOM: 539730]
| Y-o-Y | 40.03 % |
| 5 Yr CAGR | 40.03 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹635 Cr | 40.03 | |
| Mar2025 | ₹454 Cr | - | |
FREDUN PHARMACEUTICALS Operating Profit
[BOM: 539730]
| Y-o-Y | 73.29 % |
| 5 Yr CAGR | 73.29 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹91 Cr | 73.29 | |
| Mar2025 | ₹52 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 23.79 % |
| 5 Yr CAGR | 23.79 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 14.31% | 23.79 | |
| Mar2025 | 11.56% | - | |
FREDUN PHARMACEUTICALS Profit After Tax
[BOM: 539730]
| Y-o-Y | 65.28 % |
| 5 Yr CAGR | 65.28 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹33 Cr | 65.28 | |
| Mar2025 | ₹20 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 17.93 % |
| 5 Yr CAGR | 17.93 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 5.13 % | 17.93 | |
| Mar2025 | 4.35 % | - | |
FREDUN PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 539730]
| Y-o-Y | 42.61 % |
| 5 Yr CAGR | 42.61 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹60 | 42.61 | |
| Mar2025 | ₹42 | - | |
FREDUN PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 539730]
| Y-o-Y | 32.05 % |
| 5 Yr CAGR | 32.05 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 21.34% | 32.05 | |
| Mar2025 | 16.16% | - | |
FREDUN PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹2,610.2 |
| Current MarketCap | : | ₹ 1,435.6 Cr |
| Updated EOD on | : | Jun 17,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| FREDUN PHARMACEUTICALS | 16% |
13.4% |
242.1% |
| SENSEX | 4.3% |
2.6% |
-6.4% |
FREDUN PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about FREDUN PHARMACEUTICALS Financials
How the annual revenues of FREDUN PHARMACEUTICALS have changed ?
The Revenues of FREDUN PHARMACEUTICALS have increased by 40.03% YoY .
How the Earnings per Share (EPS) of FREDUN PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of FREDUN PHARMACEUTICALS has increased by 42.61 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs